Asthma Therapeutics Global Market Report 2025

Description

Asthma therapeutics refers to the various medications and treatment methods used to manage and alleviate asthma symptoms, a chronic respiratory disease marked by airway inflammation and constriction. These treatments include fast-acting medications for immediate symptom relief and long-term control drugs that reduce airway inflammation and help prevent asthma episodes.

The primary drug classes involved in asthma therapeutics include inhaled corticosteroids (ICS), long-acting beta agonists, leukotriene receptor antagonists, short-acting beta agonists, biologics, and combination inhalers. Inhaled corticosteroids are drugs inhaled directly into the lungs to decrease inflammation and swelling in the airways, improving breathing for asthma patients. These are used at different stages of treatment, such as acute care, long-term management, preventive therapy, maintenance routines, and emergency relief, and are administered through various routes including oral, inhaled, intravenous, and subcutaneous methods. They are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by different end-users, including hospitals, home care settings, and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The asthma therapeutics market research report is one of a series of new reports from The Business Research Company that provides asthma therapeutics market statistics, including asthma therapeutics industry global market size, regional shares, competitors with an asthma therapeutics market share, detailed asthma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the asthma therapeutics industry. The asthma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The asthma therapeutics market size has grown strongly in recent years. It will grow from $30.63 billion in 2024 to $33.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to increased awareness regarding asthma management, greater use of inhalers and nebulizers, a rising incidence of allergic asthma linked to pollution, enhanced government initiatives focused on respiratory health, and the expansion of healthcare infrastructure in developing economies.

The asthma therapeutics market size is expected to see strong growth in the next few years. It will grow to $44.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the increasing demand for biologics in asthma care, a heightened focus on personalized medicine, the growing adoption of digital inhalers and smart health technologies, a rising incidence of pediatric asthma, and increased investments in research and development for innovative therapeutics. Key trends expected during the forecast period include advancements in biologic treatments for severe asthma, cutting-edge inhaler technologies featuring digital tracking, the creation of personalized asthma management strategies, innovations in drug delivery systems, and the integration of artificial intelligence and wearable technology for asthma monitoring.

The rising prevalence of asthma is playing a key role in driving the growth of the asthma therapeutics market. Asthma is a chronic condition characterized by inflammation and swelling of the airways, which leads to narrowing of the passages that carry air from the nose and mouth to the lungs. This growing prevalence is largely attributed to increasing exposure to pollutants, which irritate the airways and elevate the risk of developing asthma. Asthma therapeutics are used to manage the condition by reducing inflammation, relieving symptoms, and preventing asthma attacks. Long-term control medications such as inhaled corticosteroids help minimize persistent inflammation, while quick-relief treatments like bronchodilators provide immediate symptom relief during acute episodes. For example, in April 2024, Asthma + Lung UK, a charity organization in England that supports individuals with respiratory conditions, reported that asthma-related deaths in England rose from 1,146 in 2021 to 1,236 in 2022. These statistics underscore how the increasing burden of asthma is fueling demand in the therapeutics market.

Leading companies in the asthma therapeutics industry are focusing on innovation by developing fixed-dose combination (FDC) drugs to enhance treatment effectiveness and boost patient compliance. An FDC drug contains two or more active pharmaceutical ingredients combined in a single formulation, such as an inhaler or tablet, to target specific conditions more efficiently. For instance, in June 2022, Glenmark Pharmaceuticals Limited, an Indian pharmaceutical company, introduced a new FDC drug combining Indacaterol and Mometasone for asthma treatment. Indacaterol is a long-acting beta-agonist that relaxes the airway muscles, while Mometasone is an inhaled corticosteroid that reduces inflammation in the lungs. This once-daily FDC therapy is designed to provide better symptom control and convenience, improving adherence among patients with moderate to severe asthma.

In March 2022, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired Coalesce Product Development Limited for an undisclosed sum. This acquisition was aimed at strengthening Sandoz's position in the respiratory market and expanding its expertise in developing inhalation drug-delivery systems. The move is expected to support the company's growth in asthma and other respiratory therapeutic areas. Coalesce Product Development Limited is a UK-based company, specializes in the design and development of medical devices and drug delivery systems tailored for respiratory conditions, including asthma.

Major players in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, ALK-Abello, Mylan N.V., Whanin Pharmaceutical, Mitsubishi Tanabe Pharma, Allergan plc.

North America was the largest region in the asthma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asthma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the asthma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma therapeutics market consists of revenues earned by entities by providing services such as prescription management, inhaler technique training, nebulization therapy, and allergy testing and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma therapeutics market consists of sales of methylxanthines, anticholinergics, systemic corticosteroids, mast cell stabilizers, immunotherapy products, and adjunctive therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asthma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The asthma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Inhaled Corticosteroids (ICS); Long-Acting Beta Agonists (LABA); Leukotriene Receptor Antagonists (LTRA); Short-Acting Beta Agonists (SABA); Biologics; Combination Inhalers (ICS + LABA)
2) By Treatment Stage: Acute Treatment; Long-Term Control; Preventive Treatment; Maintenance Regimens; Rescue Medications
3) By Route Of administration: Oral; Inhaled; Intravenous; Subcutaneous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Homecare; Specialty Clinics
Subsegments:
1) By Inhaled Corticosteroids (ICS): Fluticasone; Budesonide; Beclomethasone; Mometasone; Ciclesonide
2) By Long-Acting Beta Agonists (LABA): Salmeterol; Formoterol; Indacaterol; Olodaterol
3) By Leukotriene Receptor Antagonists (LTRA): Montelukast; Zafirlukast; Pranlukast
4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol); Levalbuterol; Terbutaline
5) By Biologics: Omalizumab; Mepolizumab; Benralizumab; Dupilumab; Reslizumab
6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol; Budesonide + Formoterol; Mometasone + Indacaterol; Beclomethasone + Formoterol
Companies Mentioned: Roche Holding AG; Merck & Co Inc.; Pfizer Inc.; AstraZeneca plc; Sanofi S.A.; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Amgen Inc.; Boehringer Ingelheim GmbH; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Vertex Pharmaceuticals Incorporated; Sun Pharmaceutical Industries Ltd.; Chiesi Farmaceutici S.p.A.; Cipla Limited; Mundipharma International Limited; ALK-Abello; Mylan N.V.; Whanin Pharmaceutical; Mitsubishi Tanabe Pharma; Allergan plc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r36931

1. Executive Summary

2. Asthma Therapeutics Market Characteristics

3. Asthma Therapeutics Market Trends And Strategies

4. Asthma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Asthma Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Asthma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Asthma Therapeutics Market Growth Rate Analysis
5.4. Global Asthma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Asthma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Asthma Therapeutics Total Addressable Market (TAM)

6. Asthma Therapeutics Market Segmentation

6.1. Global Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inhaled Corticosteroids (ICS)
Long-Acting Beta Agonists (LABA)
Leukotriene Receptor Antagonists (LTRA)
Short-Acting Beta Agonists (SABA)
Biologics
Combination Inhalers (ICS + LABA)
6.2. Global Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Treatment
Long-Term Control
Preventive Treatment
Maintenance Regimens
Rescue Medications
6.3. Global Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Inhaled
Intravenous
Subcutaneous
6.4. Global Asthma Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Asthma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
6.6. Global Asthma Therapeutics Market, Sub-Segmentation Of Inhaled Corticosteroids (ICS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluticasone
Budesonide
Beclomethasone
Mometasone
Ciclesonide
6.7. Global Asthma Therapeutics Market, Sub-Segmentation Of Long-Acting Beta Agonists (LABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Salmeterol
Formoterol
Indacaterol
Olodaterol
6.8. Global Asthma Therapeutics Market, Sub-Segmentation Of Leukotriene Receptor Antagonists (LTRA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Montelukast
Zafirlukast
Pranlukast
6.9. Global Asthma Therapeutics Market, Sub-Segmentation Of Short-Acting Beta Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Albuterol (Salbutamol)
Levalbuterol
Terbutaline
6.10. Global Asthma Therapeutics Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omalizumab
Mepolizumab
Benralizumab
Dupilumab
Reslizumab
6.11. Global Asthma Therapeutics Market, Sub-Segmentation Of Combination Inhalers (ICS + LABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluticasone + Salmeterol
Budesonide + Formoterol
Mometasone + Indacaterol
Beclomethasone + Formoterol

7. Asthma Therapeutics Market Regional And Country Analysis

7.1. Global Asthma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Asthma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Asthma Therapeutics Market

8.1. Asia-Pacific Asthma Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Asthma Therapeutics Market

9.1. China Asthma Therapeutics Market Overview
9.2. China Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Asthma Therapeutics Market

10.1. India Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Asthma Therapeutics Market

11.1. Japan Asthma Therapeutics Market Overview
11.2. Japan Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Asthma Therapeutics Market

12.1. Australia Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Asthma Therapeutics Market

13.1. Indonesia Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Asthma Therapeutics Market

14.1. South Korea Asthma Therapeutics Market Overview
14.2. South Korea Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Asthma Therapeutics Market

15.1. Western Europe Asthma Therapeutics Market Overview
15.2. Western Europe Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Asthma Therapeutics Market

16.1. UK Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Asthma Therapeutics Market

17.1. Germany Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Asthma Therapeutics Market

18.1. France Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Asthma Therapeutics Market

19.1. Italy Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Asthma Therapeutics Market

20.1. Spain Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Asthma Therapeutics Market

21.1. Eastern Europe Asthma Therapeutics Market Overview
21.2. Eastern Europe Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Asthma Therapeutics Market

22.1. Russia Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Asthma Therapeutics Market

23.1. North America Asthma Therapeutics Market Overview
23.2. North America Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Asthma Therapeutics Market

24.1. USA Asthma Therapeutics Market Overview
24.2. USA Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Asthma Therapeutics Market

25.1. Canada Asthma Therapeutics Market Overview
25.2. Canada Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Asthma Therapeutics Market

26.1. South America Asthma Therapeutics Market Overview
26.2. South America Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Asthma Therapeutics Market

27.1. Brazil Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Asthma Therapeutics Market

28.1. Middle East Asthma Therapeutics Market Overview
28.2. Middle East Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Asthma Therapeutics Market

29.1. Africa Asthma Therapeutics Market Overview
29.2. Africa Asthma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Asthma Therapeutics Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Asthma Therapeutics Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Asthma Therapeutics Market Competitive Landscape And Company Profiles

30.1. Asthma Therapeutics Market Competitive Landscape
30.2. Asthma Therapeutics Market Company Profiles
- 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Asthma Therapeutics Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. GlaxoSmithKline plc
31.3. Takeda Pharmaceutical Company Limited
31.4. Amgen Inc.
31.5. Boehringer Ingelheim GmbH
31.6. Teva Pharmaceutical Industries Ltd.
31.7. Regeneron Pharmaceuticals Inc.
31.8. Astellas Pharma Inc.
31.9. Vertex Pharmaceuticals Incorporated
31.10. Sun Pharmaceutical Industries Ltd.
31.11. Chiesi Farmaceutici S.p.A.
31.12. Cipla Limited
31.13. Mundipharma International Limited
31.14. ALK-Abello
31.15. Mylan N.V.

32. Global Asthma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Asthma Therapeutics Market

34. Recent Developments In The Asthma Therapeutics Market

35. Asthma Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Asthma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Asthma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Asthma Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer